Compare Stocks: IBIO, UPB, IFRX, and FULC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$3.76 -0.3%	$3.76	$2.83 ▼ $15.74	$287.64M	2.59	1.17 million shs	3.66 million shs
IBIO iBio	$1.28 +2.4%	$1.37	$0.77 ▼ $3.82	$82.31M	1.29	559,942 shs	430,646 shs
IFRX InflaRx	$2.10 +1.7%	$2.00	$0.80 ▼ $2.95	$303.58M	2.52	782,921 shs	292,676 shs
UPB Upstream Bio	$5.34 +0.6%	$6.58	$5.21 ▼ $33.68	$290.83M	1.28	565,428 shs	1.00 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	-0.27%	-1.05%	-3.84%	+1.62%	-48.63%
IBIO iBio	+2.40%	+6.22%	-14.09%	-24.26%	+127,999,900.00%
IFRX InflaRx	+1.70%	+0.24%	-1.18%	+16.07%	+77.54%
UPB Upstream Bio	+0.56%	-6.81%	-28.89%	-14.56%	-66.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$3.76 -0.3%	$3.76	$2.83 ▼ $15.74	$287.64M	2.59	1.17 million shs	3.66 million shs
IBIO iBio	$1.28 +2.4%	$1.37	$0.77 ▼ $3.82	$82.31M	1.29	559,942 shs	430,646 shs
IFRX InflaRx	$2.10 +1.7%	$2.00	$0.80 ▼ $2.95	$303.58M	2.52	782,921 shs	292,676 shs
UPB Upstream Bio	$5.34 +0.6%	$6.58	$5.21 ▼ $33.68	$290.83M	1.28	565,428 shs	1.00 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	-0.27%	-1.05%	-3.84%	+1.62%	-48.63%
IBIO iBio	+2.40%	+6.22%	-14.09%	-24.26%	+127,999,900.00%
IFRX InflaRx	+1.70%	+0.24%	-1.18%	+16.07%	+77.54%
UPB Upstream Bio	+0.56%	-6.81%	-28.89%	-14.56%	-66.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	1.75	Reduce	$8.20	118.09% Upside
IBIO iBio	3.22	Buy	$5.29	312.95% Upside
IFRX InflaRx	2.67	Moderate Buy	$7.43	254.59% Upside
UPB Upstream Bio	2.43	Hold	$29.67	455.56% Upside

Current Analyst Ratings Breakdown

Latest IBIO, UPB, IFRX, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	IFRX InflaRx	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/3/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/27/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	3.59	N/A	N/A	$6.45 per share	0.58
IBIO iBio	$100K	823.13	N/A	N/A	$1.54 per share	0.83
IFRX InflaRx	$30K	10,291.34	N/A	N/A	$0.65 per share	3.22
UPB Upstream Bio	$2.85M	102.62	N/A	N/A	$6.29 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$74.88M	-$1.21	N/A	N/A	N/A	N/A	-25.38%	-24.15%	10/29/2026 (Estimated)
IBIO iBio	-$33.04M	-$0.34	N/A	N/A	N/A	N/A	-40.66%	-35.78%	11/11/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest IBIO, UPB, IFRX, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q4 2026	IBIO iBio	-$0.0655	-$0.04	+$0.0255	-$0.07	$0.08 million	N/A
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
7/30/2026	Q2 2026	FULC Fulcrum Therapeutics	-$0.2433	-$0.34	-$0.0967	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	31.35	31.35
IBIO iBio	N/A	7.85	7.85
IFRX InflaRx	N/A	8.22	8.22
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
IBIO iBio	7.90%
IFRX InflaRx	42.39%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.30%
IBIO iBio	1.55%
IFRX InflaRx	16.30%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	55	76.30 million	70.73 million	Optionable
IBIO iBio	23	64.31 million	63.31 million	N/A
IFRX InflaRx	65	147.37 million	123.35 million	Optionable
UPB Upstream Bio	75	54.77 million	45.76 million	N/A

IBIO, UPB, IFRX, and FULC Headlines

Recent News About These Companies

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Rating of "Hold" from Analysts

September 19 at 4:13 AM | marketbeat.com

Hsbc Holdings PLC Sells 629,533 Shares of Upstream Bio, Inc. $UPB

September 18 at 3:43 AM | marketbeat.com

Squarepoint Ops LLC Buys 246,278 Shares of Upstream Bio, Inc. $UPB

September 15, 2026 | marketbeat.com

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

September 8, 2026 | quiverquant.comQ

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

September 8, 2026 | globenewswire.com

FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

September 4, 2026 | marketbeat.com

BlackRock Inc. Purchases New Holdings in Upstream Bio, Inc. $UPB

September 3, 2026 | marketbeat.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2, 2026 | theglobeandmail.com

Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

September 2, 2026 | marketbeat.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, UPB, IFRX, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$3.76 -0.01 (-0.27%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.79 +0.03 (+0.77%)

As of 09/18/2026 07:34 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

iBio NASDAQ:IBIO

$1.28 +0.03 (+2.40%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.28 0.00 (0.00%)

As of 09/18/2026 07:58 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

InflaRx NASDAQ:IFRX

$2.10 +0.04 (+1.70%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$2.08 -0.01 (-0.67%)

As of 09/18/2026 07:30 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Upstream Bio NASDAQ:UPB

$5.34 +0.03 (+0.56%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.36 +0.02 (+0.28%)

As of 09/18/2026 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, UPB, IFRX, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, UPB, IFRX, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, UPB, IFRX, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, UPB, IFRX, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

iBio NASDAQ:IBIO

InflaRx NASDAQ:IFRX

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, UPB, IFRX, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, UPB, IFRX, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, UPB, IFRX, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, UPB, IFRX, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

iBio NASDAQ:IBIO

InflaRx NASDAQ:IFRX

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools